Jessica Chitumalla
Gerontology · Ocala, FLNPI 1184022014
Payments from drug & device makers
Across 134 payments — averaging $23.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$916
- Mallinckrodt Hospital Products Inc.$371
- Otsuka America Pharmaceutical, Inc.$321
- Bayer$293
- Calliditas Therapeutics US Inc.$238
- Vifor Pharma, Inc.$229
- plus $824 from 14 others
What the payments were for
- Food & beverage$3,10997%
- Education$833%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 39 | $916 |
| Mallinckrodt Hospital Products Inc. | 10 | $371 |
| Otsuka America Pharmaceutical, Inc. | 13 | $321 |
| Bayer | 10 | $293 |
| Calliditas Therapeutics US Inc. | 11 | $238 |
| Vifor Pharma, Inc. | 14 | $229 |
| Amgen | 7 | $228 |
| Ardelyx, Inc. | 6 | $128 |
| Novartis | 5 | $84 |
| Boehringer Ingelheim | 4 | $71 |
| Fresenius USA Marketing, Inc. | 3 | $62 |
| ANI Pharmaceuticals, Inc. | 2 | $53 |
| Aurinia Pharma U.S., Inc. | 2 | $41 |
| Travere Therapeutics, Inc. | 2 | $37 |
| Akebia Therapeutics Inc | 1 | $24 |
| Scpharmaceuticals Inc. | 1 | $23 |
| OPKO Pharmaceuticals, LLC | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
| Renalytix AI, Inc. | 1 | $16 |
| Novo Nordisk | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,192 in reported general payments places this provider in the 85th percentile of 714 gerontology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 86 | $126,581 |
| JardianceEmpagliflozin | 32 | $47,724 |
| LokelmaSodium Zirconium Cyclosilicate | 21 | $34,506 |
| Calcitriol | 53 | $910 |
| Hydralazine Hcl | 17 | $545 |
| Losartan Potassium | 66 | $414 |
| Allopurinol | 26 | $275 |
| Amlodipine Besylate | 27 | $126 |
| Furosemide | 15 | $103 |
| Lisinopril | 28 | $87 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $916 | $161,087107 claims |
| Boehringer IngelheimJardiance | $71 | $47,72432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 714 gerontology providers in Florida.
Other gerontology in Ocala
- Heather YorkOcala$8K
- Noureen DhananiThe Villages$276K
- Flavius NascimentoCoral Springs$226K
- Michelle HartogWinter Park$90K
- Alejandra Rosales-CohenOrange City$88K
- Jennifer PacilettiAtlantis$66K
- Tatiana ClarkBradenton$34K
- Brandi LigonWinter Park$27K
- Boni MayOrlando$22K
- Dennis VerducciMiami$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.